Axsome Therapeutics AXSM Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's operating lease liabilities?
- Axsome Therapeutics (AXSM) reported operating lease liabilities of $22.39M in Q1 2026.
- How has Axsome Therapeutics's operating lease liabilities changed year-over-year?
- Axsome Therapeutics's operating lease liabilities decreased by 6.4% year-over-year, from $23.91M to $22.39M.
- What is the long-term trend for Axsome Therapeutics's operating lease liabilities?
- Over 3 years (2020 to 2025), Axsome Therapeutics's operating lease liabilities has grown at a 241.6% compound annual growth rate (CAGR), from $581.71K to $23.18M.
- What does operating lease liabilities mean?
- The total value of lease payments due after one year.
- How do you interpret operating lease liabilities?
- An increase indicates long-term expansion of facilities, while a decrease suggests downsizing or the conclusion of long-term lease agreements.
- How does operating lease liabilities compare across companies?
- Standardized across all industries under current lease accounting standards.